Table 3.

SARS-CoV-2 infection history and comparison across the study subgroups

	RMDs N = 1692	nr-ADs N = 400	HC N = 3918
	N (%)
Ever tested positive for SARS-CoV2	469 (28)	98 (24)	1095 (28)

	RMDs N = 469	nr-ADs N = 98	HC N = 1095
	N (%)
Asymptomatic infection	13 (3)	0 (0)	38 (3)
Required hospital admission	21 (4)	2 (2)	11 (1)
Required oxygen therapy	9 (2)	1 (1)	7 (1)
Required ICU admission	3 (0.6)	0 (0)	2 (0.2%)

	RMDs vs nr-Ads	RMDs vs HC	nrADs vs HC
	Adjusted OR (95% CI)
SARS CoV-2 infection timing
Before vaccination	1.1 (0.6–1.8)	0.6 (0.4–0.9)	0.9 (0.6–1.5)
After vaccination (B-INFs)	1.4 (0.9–2.2)	2.7 (2.1–3.5)	1.5 (0.9–2.3)
SARS CoV-2 infection frequency
Once	0.9 (0.6–1.3)	3.3 (2.8–3.9)	1.0 (0.7–1.4)
Twice or more	0.4 (0.2–0.8)	0.5 (0.4–0.8)	1.3 (0.7–2.2)

RMD rheumatic and musculoskeletal diseases, nrADs non-rheumatic autoimmune diseases, HC healthy controls, AE adverse events, OR odds ratio, CI confidence interval, B-INF breakthrough infections